MDT

89.67

-0.09%↓

VEEV

276.66

-1.93%↓

A

116.42

+2.59%↑

WBA

11.51

-0.09%↓

HQY

100.13

+2.61%↑

MDT

89.67

-0.09%↓

VEEV

276.66

-1.93%↓

A

116.42

+2.59%↑

WBA

11.51

-0.09%↓

HQY

100.13

+2.61%↑

MDT

89.67

-0.09%↓

VEEV

276.66

-1.93%↓

A

116.42

+2.59%↑

WBA

11.51

-0.09%↓

HQY

100.13

+2.61%↑

MDT

89.67

-0.09%↓

VEEV

276.66

-1.93%↓

A

116.42

+2.59%↑

WBA

11.51

-0.09%↓

HQY

100.13

+2.61%↑

MDT

89.67

-0.09%↓

VEEV

276.66

-1.93%↓

A

116.42

+2.59%↑

WBA

11.51

-0.09%↓

HQY

100.13

+2.61%↑

Search

Pacific Biosciences of California Inc

Fechado

SetorSaúde

1.38 -6.76

Visão Geral

Variação de preço das ações

24h

Atual

Mín

1.36

Máximo

1.49

Indicadores-chave

By Trading Economics

Rendimento

-428M

-426M

Vendas

-2.1M

37M

Margem de lucro

-1,146.812

Funcionários

575

EBITDA

-420M

-403M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+46.31% upside

Dividendos

By Dow Jones

Próximos Ganhos

6 de ago. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

99M

438M

Abertura anterior

8.14

Fecho anterior

1.38

Sentimento de Notícias

By Acuity

64%

36%

335 / 376 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Bullish Evidence

Pacific Biosciences of California Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

17 de jul. de 2025, 23:34 UTC

Aquisições, Fusões, Aquisições de Empresas

FTC Reopens Consent Orders for Proposed Acquisitions from Exxon Mobil, Chevron

17 de jul. de 2025, 21:14 UTC

Aquisições, Fusões, Aquisições de Empresas

Basel Medical Group Puts $1 Billion Bitcoin Purchase on Hold

17 de jul. de 2025, 21:04 UTC

Grandes Movimentos do Mercado
Aquisições, Fusões, Aquisições de Empresas

Norfolk Southern Shares Rise on WSJ Report of Union Pacific Acquisition Interest

17 de jul. de 2025, 23:43 UTC

Conversa de Mercado

Gold Edges Higher on Possible Position Adjustments -- Market Talk

17 de jul. de 2025, 23:42 UTC

Conversa de Mercado

Nikkei May Rise on Signs of U.S. Econ Strength -- Market Talk

17 de jul. de 2025, 22:47 UTC

Aquisições, Fusões, Aquisições de Empresas

FTC: Maintaining Restrictions for Former Pioneer CEO Scott Sheffield Would Damage FTC's Credibility

17 de jul. de 2025, 22:46 UTC

Aquisições, Fusões, Aquisições de Empresas

Potential Rail Merger Could Prompt Berkshire Hathaway to Bid for CSX -- Barrons.com

17 de jul. de 2025, 22:46 UTC

Aquisições, Fusões, Aquisições de Empresas

FTC Also Says Exxon Order Disregarded Guidelines and Precedent

17 de jul. de 2025, 22:43 UTC

Aquisições, Fusões, Aquisições de Empresas

FTC: Maintaining Restrictions on John Hess's Employment Would 'Damage the FTC's Credibility'

17 de jul. de 2025, 22:43 UTC

Aquisições, Fusões, Aquisições de Empresas

FTC: Chevron Order Disregarded FTC Merger Guidelines and Decades of Precedent

17 de jul. de 2025, 22:40 UTC

Aquisições, Fusões, Aquisições de Empresas

FTC Reopens and Sets Aside Chevron-Hess and Exxon-Pioneer Final Consent Orders

17 de jul. de 2025, 22:40 UTC

Aquisições, Fusões, Aquisições de Empresas

FTC Reopens and Sets Aside Chevron-Hess and Exxon-Pioneer Final Consent Orders

17 de jul. de 2025, 22:30 UTC

Conversa de Mercado
Ganhos

Netflix Sticks to Its Playbook as Competitive Landscape Changes -- Market Talk

17 de jul. de 2025, 22:20 UTC

Conversa de Mercado
Ganhos

Global Equities Roundup: Market Talk

17 de jul. de 2025, 22:20 UTC

Conversa de Mercado
Ganhos

Netflix Focusing Resources on TV Viewers It Hasn't Yet Captured -- Market Talk

17 de jul. de 2025, 22:04 UTC

Conversa de Mercado
Ganhos

Netflix Redesign Done to Match Current Capabilities -- Market Talk

17 de jul. de 2025, 22:03 UTC

Aquisições, Fusões, Aquisições de Empresas

China Threatens to Block Panama Ports Deal Unless Its Shipping Giant Is Part of It -- 2nd Update

17 de jul. de 2025, 21:58 UTC

Conversa de Mercado
Ganhos

Netflix Internal Data Doesn't Indicate Weaker Consumer Sentiment -- Market Talk

17 de jul. de 2025, 21:57 UTC

Ganhos

Netflix Earnings Soar Past Expectations. How a Weak Dollar Helped Boost Results. -- Barrons.com

17 de jul. de 2025, 21:47 UTC

Ganhos

Netflix Raises Revenue, Margin Forecasts After Strong Second Quarter -- Update

17 de jul. de 2025, 21:45 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

17 de jul. de 2025, 21:45 UTC

Conversa de Mercado

Crypto Bills Welcomed by Venture Capital, Trade Group Says -- Market Talk

17 de jul. de 2025, 21:38 UTC

Aquisições, Fusões, Aquisições de Empresas

Railroad Operator Union Pacific Exploring Deal for Norfolk Southern -- 2nd Update

17 de jul. de 2025, 21:22 UTC

Aquisições, Fusões, Aquisições de Empresas

Update: Union Pacific Considering a Norfolk Southern Buyout: Report. -- Barrons.com

17 de jul. de 2025, 21:05 UTC

Ganhos

Netflix Earnings Soar Past Expectations. How a Weak Dollar Helped Boost Results. -- Barrons.com

17 de jul. de 2025, 21:04 UTC

Aquisições, Fusões, Aquisições de Empresas

Railroad Operator Union Pacific Exploring Deal for Norfolk Southern -- Update

17 de jul. de 2025, 21:02 UTC

Aquisições, Fusões, Aquisições de Empresas

Union Pacific Considering a Norfolk Southern Buyout: Report. -- Barrons.com

17 de jul. de 2025, 20:59 UTC

Aquisições, Fusões, Aquisições de Empresas

Basel Medical Group Puts $1B Bitcoin Purchase on Hold

17 de jul. de 2025, 20:50 UTC

Conversa de Mercado
Ganhos

Tech, Media & Telecom Roundup: Market Talk

17 de jul. de 2025, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

Comparação entre Pares

Variação de preço

Pacific Biosciences of California Inc Previsão

Preço-alvo

By TipRanks

46.31% parte superior

Previsão para 12 meses

Média 2.18 USD  46.31%

Máximo 3 USD

Mínimo 1.25 USD

Com base em 7 analistas de Wall Street que oferecem metas de preço de 12 meses para Pacific Biosciences of California Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

7 ratings

4

Comprar

3

Manter

0

Vender

Pontuação Técnica

By Trading Central

1.13 / N/ASuporte e Resistência

Curto Prazo

Bullish Evidence

Médio Prazo

Bearish Evidence

Longo Prazo

Weak Bearish Evidence

Sentimento

By Acuity

335 / 376 Ranking em Saúde

Sentimento de Notícias

Evidência de Tendência de Baixa

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Pacific Biosciences of California Inc

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, it provides revio system + sequel systems which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. The company serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. It markets its products through a sales force and distribution partners in Asia, Australia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.